Isavuconazole in Critically Ill Patients: Efficacy and Safety

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShanghai 10th People's Hospital

About this trial

Due to factors such as disease status, gastrointestinal conditions, commonly used medications (e.g., vasopressors), and cardiac output, the plasma concentration of isavuconazole in critically ill patients may differ from that in healthy individuals, exhibiting significant variability.

This study aims to explore the variability of isavuconazole plasma concentrations in critically ill patients and its correlation with efficacy and adverse effects. The research includes:

1. The distribution and variability of isavuconazole plasma concentrations in critically ill patients; 2. Clinical outcomes; 3. Adverse effects.

Eligibility criteria

Qualifiers

Adult critically ill patients (≥18 years) admitted to ICU with suspected or confirmed invasive fungal infection (IFI)

IFI diagnosis per EORTC/MSGERC 2019 criteria

Disqualifiers

Drug allergy

Inherited short QT syndrome

Contraindications for nasogastric/oral drug delivery

<18 years old

Trial design

Treatments tested in this trial

  • Isavuconazole treatment

Treatment groups

75 Participants
are divided into 1 treatment group

Locations

This trial has no locations